Factors Associated With Symptomatic Interstitial Lung Disease in Patients With Systemic Sclerosis (SSc-ILD)

被引：0
|
作者：
Chaichatpornsuk, V. [1 ]
Teerapuncharoen, K. [1 ]
Muangchan, C. [1 ]
机构：
[1] Siriraj Hosp, Dept Med, Bangkok, Thailand
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1834
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
    Al-Adwi, Yehya
    Westra, Johanna
    van Goor, Harry
    van Kempen, Leon. C. L. T.
    Timens, Wim
    Gan, C. Tji
    Mulder, Douwe J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1587 - 1589
  • [42] EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL
    Allanore, Y.
    Hoffmann-Vold, A. M.
    Mayes, M.
    Vonk, M.
    Miede, C.
    Alves, M.
    Riemekasten, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 162 - 162
  • [43] Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Highland, Kristin B.
    Kuwana, Masataka
    Azuma, Arata
    Fischer, Aryeh
    Maher, Toby M.
    Mayes, Maureen D.
    Raghu, Ganesh
    Girard, Mannaig
    Kohlbrenner, Veronika
    Clerisme-Beaty, Emmanuelle
    Alves, Margarida
    Distler, Oliver
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [44] GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL
    Maher, Toby
    Highland, Kristin
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Kohlbrenner, Veronika
    Kuwana, Masataka
    Distler, Oliver
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 831 - 832
  • [45] TO EVALUATE THE PREVALENCE OF INTERSTITIAL LUNG DISEASE (ILD) AND/OR PULMONARY ARTERIAL HYPERTENSION (PAH) IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC) AND TO DETERMINE THE FACTORS ASSOCIATED WITH ILD
    Ortega Castro, R.
    Mariscal-Ocana, R.
    Rojas-Gimenez, M.
    Calvo Gutierrez, J.
    Escudero Contreras, A.
    Lopez-Medina, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1253 - 1253
  • [46] Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Kreuter, M.
    Highland, K. B.
    Kuwana, M.
    Azuma, A.
    Maher, T.
    Mayes, M. D.
    Raghu, G.
    Girard, M.
    Kohlbrenner, V
    Clerisme-Beaty, E.
    Alves, M.
    Distler, O.
    PNEUMOLOGIE, 2020, 74 : S55 - S56
  • [47] Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Highland, Kristin B.
    Azuma, Arata
    Fischer, Aryeh
    Kuwana, Masataka
    Maher, Toby M.
    Mayes, Maureen D.
    Raghu, Ganesh
    Girard, Mannaig
    Alves, Margarida
    Gahlemann, Martina
    Distler, Oliver
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [48] Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
    Wiewrodt, R.
    Raghu, G.
    Distler, O.
    Azuma, A.
    Highland, K. B.
    Kuwana, M.
    Mayes, M. D.
    Wachtlin, D.
    Stowasser, S.
    Alves, M.
    Gahlemann, M.
    Maher, T. M.
    PNEUMOLOGIE, 2020, 74 : S58 - S59
  • [49] Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
    Raghu, Ganesh
    Distler, Oliver
    Azuma, Arata
    Fischer, Aryeh
    Highland, Kristin B.
    Kuwana, Masataka
    Mayes, Maureen D.
    Wachtlin, Daniel
    Stowasser, Susanne
    Alves, Margarida
    Gahlemann, Martina
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [50] Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
    Kreuter, M.
    Highland, K. B.
    Azuma, A.
    Kuwana, M.
    Maher, T. M.
    Mayes, M. D.
    Raghu, G.
    Girard, M.
    Alves, M.
    Gahlemann, M.
    Distler, O.
    PNEUMOLOGIE, 2020, 74 : S56 - S57
12345